1. Home
  2. Analysis
  3. Reyataz
  4. Singulair

Reyataz and Singulair drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Reyataz (atazanavir sulfate) and Singulair (montelukast sodium). Common drug interactions include chronic kidney disease among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Reyataz and Singulair. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Reyataz?

Reyataz has active ingredients of atazanavir sulfate. It is often used in hiv infection. eHealthMe is studying from 11,386 Reyataz users. Check the latest studies of Reyataz.

What is Singulair?

Singulair has active ingredients of montelukast sodium. It is often used in asthma. eHealthMe is studying from 129,752 Singulair users. Check the latest studies of Singulair.

On Jul, 25, 2026

50 people who take Reyataz and Singulair together, and have interactions are studied.

Reyataz and Singulair drug interactions.

What are the common drug interactions of Reyataz and Singulair, by gender? *:

female:

  1. Chronic kidney disease
  2. Quality of life decreased
  3. Alcohol poisoning
  4. Atelectasis (partial or complete collapse of the lung)
  5. Back injury
  6. Back pain
  7. Bipolar disorder (mood disorder)
  8. Bone density decreased
  9. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  10. Cellulitis (infection under the skin)

male:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Bone loss
  4. Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)
  5. Foot fracture
  6. Impaired work ability
  7. Mobility decreased (ability to move is reduced)
  8. Anger
  9. Ankle fracture
  10. Compression fracture (fracture due to pressure caused by injury)

What are the common drug interactions of Reyataz and Singulair, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Post herpetic neuralgia (neuralgia caused by the varicella zoster virus)
  2. Premature delivery
  3. Sexual dysfunction (difficulty experienced by an individual or a couple during any stage of a normal sexual activity)
  4. Weight increased
  5. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  6. Anxiety
  7. Decreased activity
  8. Depression
  9. Dyspnoea (difficult or laboured respiration)
  10. Emotional distress

30-39:

  1. Blood hiv rna increased
  2. Viral load increased
  3. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  4. Emotional distress
  5. Pain
  6. Humerus fracture (injury to the upper arm bone)
  7. Tooth loss
  8. Upper limb fracture
  9. Arthralgia (joint pain)
  10. Fracture

40-49:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Emotional distress
  4. Pain
  5. Depression
  6. Osteoporosis (bones weak and more likely to break)
  7. Anger
  8. Ankle fracture
  9. Bone density decreased
  10. Chronic kidney disease

50-59:

  1. Emotional distress
  2. Pain
  3. Renal failure (kidney dysfunction)
  4. Chronic kidney disease
  5. Renal impairment (severely reduced kidney function)
  6. Bone loss
  7. Depression
  8. Gout (uric acid crystals building up in the body)
  9. Multiple fractures
  10. Osteonecrosis (death of bone)

60+:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Dysstasia (difficulty in standing)
  4. Emotional distress
  5. Multiple fractures
  6. Osteoporosis (bones weak and more likely to break)
  7. Pain
  8. Quality of life decreased

What are the existing conditions these people have? *

  1. Pain: 6 people, 12.00%
  2. Hypersensitivity: 6 people, 12.00%
  3. High Blood Cholesterol: 5 people, 10.00%
  4. Insomnia (sleeplessness): 5 people, 10.00%
  5. Depression: 5 people, 10.00%
  6. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 5 people, 10.00%
  7. Viral Infection: 4 people, 8.00%
  8. Bipolar Disorder (mood disorder): 4 people, 8.00%
  9. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 8.00%
  10. Fungal Infection: 4 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Reyataz and Singulair?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Reyataz and Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Reyataz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Singulair:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Reyataz and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Singulair and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on atazanavir sulfate and montelukast sodium (the active ingredients of Reyataz and Singulair, respectively), and Reyataz and Singulair (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.